it's about putting every last dollar into that growth and infrastructure that when we hit our pre-commercial launch year for the therapeutics business, we are really ready to go.

Jul 28, 2026 / receipt

Our investments are focused on building the operational strength needed to unlock these markets and then of course to scale sustainably.

Jul 28, 2026 / receipt

In this half, we have made a significant investment into our global manufacturing and infrastructure to ensure that we are well positioned for long-term growth.

Jul 28, 2026 / receipt

of $4.8 million, employment costs, sales commissions and travel costs related to sales and marketing personnel. Manufacturing and distribution costs were $30.1 million and general and administration costs were $12.0 million for our Manufacturing Solutions segment for the year ended December 31, 2025 (compared to $11.4 million and $4.0 million for the year ended December 31, 2024 , respectively).

filing / Feb 20, 2026 / receipt

The goodwill arising is attributable to the acquired workforce, anticipated future cost savings from utilizing RLS' radiopharmaceutical distribution capabilities and synergies of integrating the business within the Group.

filing / Feb 20, 2026 / receipt

Expand our global infrastructure for product delivery To develop and deliver radiopharmaceuticals, which have a relatively short shelf life due to their unique properties, supply chain, manufacturing and logistics are vitally important.

filing / Feb 20, 2026 / receipt

General and administration costs were $22.3 million in 2025 , compared to $27.8 million in 2024 , reflecting operating leverage and stabilization in corporate activities and related overheads.

filing / Feb 20, 2026 / receipt

It expands our global production network which includes in-house and partner facilities. Originally opened in 2018, the site comprises a cyclotron and multiple production hot cells and was designed and built by JFE Engineering ("JFE") as the Contract Manufacturing Organization ("CMO") for TLX250-Px in Japan and China, including for the ZIRCON-CP study.

filing / Feb 20, 2026 / receipt

Our principal headquarters are located in Melbourne, Australia where we lease office space and have a separate R&D facility.

filing / Feb 20, 2026 / receipt

The way that we manage pricing and pricing consistency is by ongoing innovation and capability delivery to our customers and differentiating ourselves | Position your solution as a tool that accelerat

company_statement / Jul 28, 2026 / receipt

there's some genuine clinical and and clinical workflow benefits that comes from that product. | Align your offering with their goal of delivering tangible clinical workflow benefits, as this is a key

company_statement / Jul 28, 2026 / receipt

we have been granted a Hickspix code for our life cycle management product. Um, which by the way has innovative aspects in its own right. | The company is investing in a lifecycle management product w

company_statement / Jul 28, 2026 / receipt

you know, it was a pretty uh pretty painful study protocol. | Target clinical operations with solutions that streamline or automate complex study protocols, as the company has acknowledged recent fric

company_statement / Jul 28, 2026 / receipt

As a data driven organization, our decisions are grounded in rigorous scientific and clinical evidence, ensuring that we prioritize our limited resources | Lead with data analytics and business intell

company_statement / Jul 28, 2026 / receipt

radiopharmaceutical manufacturing and distribution is an extremely complex business from an operational quality and regulatory perspective. | Address the CEO's stated pain point by highlighting how yo

company_statement / Jul 28, 2026 / receipt